It priced more than 21.2 million shares at $18 apiece, exceeding expectations it originally set in a filing last week. The company will begin trading on Nasdaq on Thursday under the ticker symbol “BRVE.” under the ticker symbol “BRVE.” Braveheart is the third cardiac drug developer, and second with a program or portfolio licensed from a Chinese pharmacetical firm, to price an IPO so far this year. Most of those companies’ shares trade at higher values than when they debuted, too.